News und Analysen
![Sensorion to participate in Chardan’s Annual Genetic Medicines & Cell Therapy Manufacturing Summit and Kempen’s Life Sciences Conference: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK0dxVmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--df3db62501cd2dac51e6a4832a420790d1de65b6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo-sensorion2.jpg?locale=de)
Sensorion to participate in Chardan’s Annual Genetic Medicines & Cell Therapy Manufacturing Summit and Kempen’s Life Sciences Conference
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, is pleased to announce its participation
![EQS-News: Sernova Announces Research Collaboration with AstraZeneca to Evaluate Novel Potential Therapeutic Cell Applications](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
EQS-News: Sernova Announces Research Collaboration with AstraZeneca to Evaluate Novel Potential Therapeutic Cell Applications
EQS-News: Sernova Announces Research Collaboration with AstraZeneca to Evaluate Novel Potential Therapeutic Cell Applications
![Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
![EQS-News: BB BIOTECH AG: Creating blockbuster drugs using algorithms](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
EQS-News: BB BIOTECH AG: Creating blockbuster drugs using algorithms
EQS-News: BB BIOTECH AG: Creating blockbuster drugs using algorithms
![Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares
Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares
![EQS-News: Abivax: Publication of an expert article in JCC on obefazimod as promising therapeutic management option for UC patients](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
EQS-News: Abivax: Publication of an expert article in JCC on obefazimod as promising therapeutic management option for UC patients
EQS-News: Abivax: Publication of an expert article in JCC on obefazimod as promising therapeutic management option for UC patients
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
![Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule
Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule
![EQS-News: Development of Vita 34 AG in 2022 stressed by weakened consumption power of consumers along with one-off effects](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
EQS-News: Development of Vita 34 AG in 2022 stressed by weakened consumption power of consumers along with one-off effects
EQS-News: Development of Vita 34 AG in 2022 stressed by weakened consumption power of consumers along with one-off effects
![Abivax postpones the publication of its 2023 Universal Registration Document](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Abivax postpones the publication of its 2023 Universal Registration Document
Abivax postpones the publication of its 2023 Universal Registration Document
![Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
![Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![MD Medical Group Investments Plc: MD Medical Group announces operating results for Q1 2023](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
MD Medical Group Investments Plc: MD Medical Group announces operating results for Q1 2023
MD Medical Group Investments Plc: MD Medical Group announces operating results for Q1 2023
![Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
![EQS-News: MPH Health Care AG: Preliminary IFRS result 2022](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
EQS-News: MPH Health Care AG: Preliminary IFRS result 2022
EQS-News: MPH Health Care AG: Preliminary IFRS result 2022
![EQS-News: Formycon publishes results for financial year 2022](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
EQS-News: Formycon publishes results for financial year 2022
EQS-News: Formycon publishes results for financial year 2022
![Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023
Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023
![MD Medical Group Investments Plc: The results of the Annual General Meeting of shareholders](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
MD Medical Group Investments Plc: The results of the Annual General Meeting of shareholders
MD Medical Group Investments Plc: The results of the Annual General Meeting of shareholders
![Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![Convatec Group PLC: HOL-Holding(s) in Company](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Convatec Group PLC: HOL-Holding(s) in Company
Convatec Group PLC: HOL-Holding(s) in Company
![EQS-Adhoc: Vita 34 AG publishes outlook for the 2023 financial year](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
EQS-Adhoc: Vita 34 AG publishes outlook for the 2023 financial year
EQS-Adhoc: Vita 34 AG publishes outlook for the 2023 financial year
![EQS-Adhoc: Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
EQS-Adhoc: Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance
EQS-Adhoc: Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance
![Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc